If approved, levacetylleucine could become the first therapy on the market for ataxia-telangiectasia.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the submission of its clinical trial application (CTA) for Study SRP-1005-101, ...

With schools opening back up after the festive break, the NHS has issued a warning to parents for when they need to keep their children at home. This comes after cases of flu skyrocketed across the UK ...

The 2025-2026 flu season is surging in the U.S. and New Jersey, where there's been increased severity of influenza A, with further testing from the CDC showing many NJ residents have the emerging ...

Flu season has taken off nationwide, with cases rising rapidly in some parts of the country over the past few weeks. “We’ve seen sustained, elevated activity across multiple key indicators in many ...

It's the holiday season, which means it's the most common time of year for norovirus to spread. Here's what you need to know about this winter stomach bug. Silver Cross Hospital in Will County ...

After a very warm and enjoyable fall, we saw the temperatures drop as fall finally settled into central Ohio. With this change in weather has come the inevitable increase in patients coming into the ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--$QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the ...

Children all over the country grew up watching Bill Nye the Science Guy explain a variety of scientific terms to them. And now, the 69-year-old is ready to do so again. In a recent sitdown with ...

Sign up for the Slatest to get the most insightful analysis, criticism, and advice out there, delivered to your inbox daily. Look up polycystic ovary syndrome, or ...

The U.S. Food and Drug Administration has approved a version of leucovorin made by GlaxoSmithKline, years after the company pulled the drug from consideration when it stopped manufacturing it. The ...